REGN vs BIIB vs VRTX vs INCY vs BMRN

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Incyte Corporation (INCY) offers the better valuation at 15. 3x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

3x versus BioMarin Pharmaceutical Inc. at 30. 1x. On forward P/E, BioMarin Pharmaceutical Inc. is actually cheaper at 12. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 68x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +97.

7%, compared to -30. 4% for BioMarin Pharmaceutical Inc. (BMRN). Over 10 years, the gap is even starker: VRTX returned +382. 6% versus BMRN's -35. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 64β versus Incyte Corporation's 0. 87β — meaning INCY is approximately 37% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 38% for Biogen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, BMRN leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus 10. 8% for BioMarin Pharmaceutical Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus 16. 6% for BMRN. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 68x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, BioMarin Pharmaceutical Inc. (BMRN) trades at 12. 6x forward P/E versus 22. 2x for Vertex Pharmaceuticals Incorporated — 9. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 65. 6% to $89. 64.

In this comparison, REGN (0.

5% yield) pays a dividend. BIIB, VRTX, INCY, BMRN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

82), +382. 6% 10Y return). Both have compounded well over 10 years (VRTX: +382. 6%, INCY: +34. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: REGN is a mid-cap deep-value stock; BIIB is a mid-cap quality compounder stock; VRTX is a mid-cap quality compounder stock; INCY is a mid-cap high-growth stock; BMRN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.